Seeking Alpha

M. E. Garza

View as an RSS Feed
View M. E. Garza's Comments BY TICKER:
Latest  |  Highest rated
  • David And Goliath Case Offers A Surprising Opportunity [View article]
    Lots of good news flow appears to be set for DECN. We liked it at $.17 and continue to think it will probably be taken out by BP. This is a huge market with big markups!
    Oct 21 06:33 PM | Likes Like |Link to Comment
  • Resistance (To Resistance) Is Futile: The Growing Opportunity For Trius And Tedizolid [View article]
    Awesome work as always David!
    Dec 21 03:06 AM | Likes Like |Link to Comment
  • Amarin Announces Submission of Supplemental New Drug Application for Chemport, Inc. as an Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier [View article]
    Canaccord Genuity biotechnology analyst Ritu Baral lowered her price target on Amarin (AMRN) from $19 to $17, based on an analysis of launch costs for Vascepa, which is being developed to lower high levels of triglycerides in adults.

    Ms. Baral said “We are adjusting our P&L assumptions after additional research and analysis around a self-launch scenario. Our $17 target is based on a sum-of-the-parts analysis, combining a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales.”

    Ms. Baral added: “We continue to expect business development talks to intensify and Vascepa to receive NCE (five-year exclusivity).”

    Ms. Baral adjusted her 2012 EPS estimates to $(1.49) from $(1.46) and 2013 EPS estimates to $(2.42) from $0.28. Ms. Baral also adjusted her annual revenue for 2013 to $87.4M from $110.7M and lowered her price target to $17.00 from $19.00.
    Dec 20 09:03 AM | Likes Like |Link to Comment
  • Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid [View article]
    $PSTI is really a no-brainer right now. Upcoming clinical news and buying coming in next month from funds in Israel. Plus, there are rumors of partnerships for some of these technologies. Add it up and you'll see why they are touting this $8 price target on PSTI shares.
    Dec 6 03:06 PM | Likes Like |Link to Comment
  • Let's Watch Amarin Get Crushed By Wall Street [View article]
    Fact is, the company is in talks with several big pharma and specialty pharma companies for a buyout. That is a FACT.

    Despite all the noise and shaking of loose hands in the stock, the only question that matters is... "How much will AMRN fetch in the buyout that is coming?"
    Oct 12 10:01 AM | 5 Likes Like |Link to Comment
  • Dilution Is The Solution To Pollution [View article]
    PSTI will certainly move on a number of pending news/catalyst events. It has certainly transformed into a great biotech bet.
    Oct 10 10:25 AM | 2 Likes Like |Link to Comment
  • Why Neuralstem Could Provide A 10x Return [View article]
    While it is true that you need FDA approval for a drug distribution in the US a Personal Autologos Stem Cell treatment is a different story as it is not distributed.

    ALS patients would easily and happily go to Israel for treatment once the Israeli Health regulatory system would approve such treatment after phase III. Israel has a wonderful record when it comes to Bio Tech and their Health System is one of the best in the western world.

    Keep an eye on $BCLI
    Sep 12 03:06 AM | 1 Like Like |Link to Comment
  • Why Neuralstem Could Provide A 10x Return [View article]
    BCLI-- now there is an emerging company to watch in the ALS space.
    Especially compelling when you consider some of the compassionate use results and early data.

    Very much undiscovered and not paying writers to pump it.

    I'm just sayin'. ;)
    Sep 12 02:06 AM | Likes Like |Link to Comment
  • Amarin Path Clearer After FDA Approval [View article]
    $AMRN is a screaming buy at these levels. Even if it retraces down to the next fibonnacci level, who cares? This is a $27 stock waiting to happen past FDA approval.
    Jul 30 09:06 AM | 2 Likes Like |Link to Comment
  • If AMR101 Is Approved, Sell Amarin [View article]
    Wow! I can't believe the editors at Seeking Alpha let this through the system to be published. Perhaps this was meant as an InstaBlog?
    Jul 25 06:12 AM | 2 Likes Like |Link to Comment
  • Keryx: A Lot Can Go Wrong At $2 [View article]
    A lot can go wrong when writing an article about a $2 stock, too, it seems. :(
    Jul 14 10:07 AM | 2 Likes Like |Link to Comment
  • Amarin Valuation Before FDA Action [View article]
    Very logical presentation on $AMRN. With almost 4 million people suffering from TG levels greater than 500 mg/dL in this country alone (and getting worse), it's clear to see that there are billions to be made here for years to come.
    Jul 12 04:19 PM | 2 Likes Like |Link to Comment
  • Amarin Is A Hold [View article]
    $AMRN is a winner through and through. Today's bear raid sets the table for a great upside trade.
    Jul 11 01:19 AM | Likes Like |Link to Comment
  • Orphan Drug Approval For Medgenics' Hepatitis Therapy Makes It Big Pharma Target [View article]
    Actually, it's a brilliant implantable technology that has multiple applications.. Check out the presentation here: http://slidesha.re/O04sLW
    Jun 21 04:34 PM | Likes Like |Link to Comment
  • 2 Healthcare Stocks That May Surprise In The Near Term [View article]
    Looks like Wall Street may finally be starting to jump on the OMPI bandwagon. Good for our readers who got in at $8+ - Congrats. Stock starting to move big today. More winners coming!
    Jun 6 10:21 AM | Likes Like |Link to Comment
COMMENTS STATS
123 Comments
89 Likes